High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy

被引:56
|
作者
Kim, Sang Yeop [1 ]
Yu, Minzhi [1 ]
Morin, Emily E. [1 ]
Kang, Jukyung [1 ]
Kaplan, Mariana J. [2 ]
Schwendeman, Anna [1 ]
机构
[1] Univ Michigan, North Campus Res Ctr,2800 Plymouth Rd, Ann Arbor, MI 48109 USA
[2] NIAMSD, NIH, Bethesda, MD 20892 USA
关键词
APOLIPOPROTEIN-A-I; C-REACTIVE PROTEIN; METHIONINE OXIDATION; ANTIINFLAMMATORY PROPERTIES; MIMETIC PEPTIDE; ERYTHEMATOSUS PATIENTS; CHOLESTEROL TRANSPORT; LIPID-PEROXIDATION; RECONSTITUTED HDL; BINDING LECTIN;
D O I
10.1002/art.41059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic lupus erythematosus (SLE) patients exhibit accelerated development of atherosclerosis and increased incidents of cardiovascular disease (CVD) that cannot be explained by traditional risk factors alone. Accumulating evidence suggests that reduced levels of high-density lipoproteins (HDLs), along with altered HDL composition and function, may contribute to the accelerated atherosclerosis in SLE patients. Normally, HDLs play various atheroprotective roles through facilitating cholesterol efflux, inhibiting vascular inflammation, and scavenging oxidative species. However, systemic inflammation, oxidative stress, and autoimmunity in SLE patients induce changes in HDL size distribution and proteomic and lipidomic signatures. These compositional changes in HDLs result in the formation of proinflammatory, dysfunctional HDL. These lupus-altered HDLs have impaired antiatherogenic function with reduced cholesterol efflux capacities, impaired antioxidation abilities, and diminished antiinflammatory properties. In fact, dysfunctional HDL may promote atherogenesis by inducing inflammation. Thus, dysfunctional HDLs could be an important biomarker of accelerated atherosclerosis in lupus. Additionally, HDL-targeted therapies, especially infusion of reconstituted HDLs, may serve as a potential therapeutic intervention for SLE patients with CVD.
引用
收藏
页码:20 / 30
页数:11
相关论文
共 50 条
  • [41] HIGH-DENSITY LIPOPROTEIN AND CORONARY HEART-DISEASE
    BIALE, Y
    HAREFUAH, 1977, 93 (3-4) : 104 - 105
  • [42] HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN CEREBROVASCULAR-DISEASE
    NUBIOLA, AR
    MASANA, L
    MASDEU, S
    RUBIESPRAT, J
    ARCHIVES OF NEUROLOGY, 1981, 38 (07) : 468 - 468
  • [43] Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease
    Liao, Dan
    Yang, Xiaofeng
    Wang, Hong
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (12) : 1652 - 1659
  • [44] HIGH-DENSITY LIPOPROTEIN AND CORONARY HEART-DISEASE
    BETTERIDGE, DJ
    BRITISH MEDICAL JOURNAL, 1989, 298 (6679): : 974 - 975
  • [45] High-density lipoprotein changes in coronary artery disease
    Miwa, K
    CARDIOVASCULAR RESEARCH, 1998, 40 (02) : 419 - 419
  • [46] High-Density Lipoprotein Function and Dysfunction in Health and Disease
    Scott T. Chiesa
    Marietta Charakida
    Cardiovascular Drugs and Therapy, 2019, 33 : 207 - 219
  • [47] High-density lipoprotein carbamylation and dysfunction in vascular disease
    Santana, Jeans M.
    Brown, Clinton D.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2018, 23 : 2227 - 2234
  • [48] HIGH-DENSITY LIPOPROTEIN AND PERIPHERAL VASCULAR-DISEASE
    KIRSTEIN, P
    OLSSON, AG
    LANCET, 1979, 1 (8108): : 154 - 154
  • [49] HIGH-DENSITY LIPOPROTEIN AND CORONARY HEART-DISEASE
    MJOS, OD
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1977, 37 (03): : 191 - 193
  • [50] HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND LIVER-DISEASE
    KANEL, GC
    RADVAN, G
    PETERS, RL
    HEPATOLOGY, 1983, 3 (03) : 343 - 348